<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00098020</url>
  </required_header>
  <id_info>
    <org_study_id>050015</org_study_id>
    <secondary_id>05-DK-0015</secondary_id>
    <nct_id>NCT00098020</nct_id>
  </id_info>
  <brief_title>Podocyte Retinoids</brief_title>
  <official_title>Retinoids for Podocyte Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study of retinoids for patients with unsatisfactory response to conventional
      treatment of nephrotic syndrome due to focal segmental glomerulosclerosis or minimal change
      disease, two renal disorders associated with putatively pathogenic malfunctioning of
      glomerular podocytes. The hypothesis that retinoids may have reparative effects on these
      cells is based on previous research showing that retinoids promote the differentiation or
      redifferentiation of aberrant epithelial cells. Results obtained by 6 months of treatment
      with retinoids (that have been approved for non-renal indications) will be used as
      preliminary information upon which to base further testing of these agents in formal clinical
      trials in refractory cases of these nephrotic syndromes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Retinoids are analogues of vitamin A that regulate cellular differentiation, leading to
      therapeutic use in skin diseases and malignancy. In animal models of kidney diseases,
      retinoids restore podocyte phenotype toward normal and reduce proteinuria. The objective of
      this phase II trial is to evaluate safety and develop preliminary evidence of efficacy of
      retinoid treatment in patients with podocyte disease. The study design is an open-label trial
      of isotretinoin (13-cis retinoic acid). The study will be performed under the auspices of an
      investigational new drug (IND) from the FDA. We will enroll 10 adult patients with
      biopsy-proven minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), or
      collapsing glomerulopathy (CG). Inclusion criteria will include a prior trial of
      immunosuppressive therapy and proteinuria greater than or equal to 3.5 g/d while on
      angiotensin antagonist therapy.

      The duration of the trial will be 6 months with possible additional 6-month extension for
      patients who only develop partial response (PR) or limited response (LR). Those who have
      complete response (CR) will continue the treatment for one additional month, for no more than
      7 months total. Non-responders will stop at the end of 6 months. The primary clinical
      endpoint will be reduction in proteinuria as compared to the baseline value assessed by
      paired t test. The secondary clinical endpoints will be the fraction of patients who achieve
      CR or PR at 6 months and at one year, confirmed on urine collections four weeks apart.
      Retinoid therapy will be discontinued at the time a CR is confirmed, one month after the
      first detection of CR. Follow-up will last one year after cessation of drug therapy. Patients
      who have had a CR or PR but experience a relapse with &gt;2.0g/g proteinuria during follow-up
      will be eligible for further retinoid therapy. Patients will undergo a renal biopsy prior to
      initiating therapy, in order to evaluate the extent of glomerular injury and interstitial
      fibrosis, unless they have had a kidney biopsy within the preceding 24 months that is
      available for review. Laboratory endpoints will include serum and urine cytokine levels and
      urine levels of podocyte proteins, including nephrin. Toxicity screening will include serum
      and urine chemistries, psychological profiles, radiographic films of cervical, thoracic
      spines and calcanei, and bone mass assessment with dual photon excitation absorptiometry
      (DEXA) at spine and hip.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 26, 2004</start_date>
  <completion_date type="Actual">June 27, 2016</completion_date>
  <primary_completion_date type="Actual">June 27, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Phase II, open-label pilot study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Proteinuria at Week 24 From Baseline</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Change of proteinuria at Week 24 compared to the baseline using protein/creatinine ratio (PCR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Are in Complete Remission (CR) or Partial Remission (PR) at 6 Months or at the End of One Year.</measure>
    <time_frame>End of one year from baseline</time_frame>
    <description>Based on 24hour proteinuria, response outcomes are defined as CR (complete remission): &lt;0.3 g/g PR (partial remission): 50% fall from baseline and &lt;2.0 g/g</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Collapsing Glomerulopathy</condition>
  <condition>Glomerulosclerosis, Focal Segmental</condition>
  <arm_group>
    <arm_group_label>Isotretinoin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be treated with Isotretinoin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotretinoin</intervention_name>
    <arm_group_label>Isotretinoin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

          -  Patients with podocyte diseases, MCD, FSGS (including primary, secondary, and adaptive
             variants), and CG (including HIV-associated variant), who meet the following criteria:

             --An adequate renal biopsy, defined as having minimum 10 glomeruli for light
             microscopy and minimum 3 glomeruli for electron microscopy, unless the podocyte
             disease is diagnostic on fewer glomeruli. Patients who have non-diagnostic or
             technically inadequate biopsies will be offered the opportunity to undergo a research
             biopsy to determine eligibility. For some patients who have had a non-diagnostic or
             technically inadequate biopsy, a repeat renal biopsy may be clinically indicated in an
             effort to diagnose and treat a potentially serious kidney disease.

          -  Greater than or equal to 16 years of age. The rationale for excluding younger children
             is that retinoids may carry greater toxicity in children, as there are reports of
             premature epiphyseal closure, development of slender long bones, and periostal
             thickening.

          -  Prior treatment with at least two immunosuppressive agents that have been shown to
             induce remission in MCD and FSGS: glucocorticoids, cyclosporine, tacrolimus,
             cyclophosphamide, chlorambucil, and mycophenolate mofetil. Therapy with each agent
             must last at least 8 weeks. Exemptions will be made for those with contraindications
             to these medications or those who cannot tolerate these medications. The rationale is
             to recruit patients who have failed conventional therapy. All patients will be off
             immunosuppression for at least 4 weeks before starting retinoids in order to avoid a
             confounding effect.

          -  Three first void urine protein/creatinine ratios &gt; 2 g/g obtained within one month
             prior to enrolling in the study. These urine collections will be obtained after the
             patient has been on a stable dose of angiotensin converting enzyme(ACE) inhibitor or
             angiotensin receptor blocker (ARB) for at least 4 weeks (the maximal antiproteinuric
             effect of these medications occurs after 4 weeks). The rationale is that patients with
             nephrotic-range proteinuria are at high risk for progressive renal disease, justifying
             participation in a clinical trial with novel agents. Patients with steroid-sensitive
             frequently relapsing MCD will not be required to have used ACE inhibitor or ARB, as
             steroids alone are typically sufficient therapy to induce remission.

          -  If hypertensive: blood pressure of less than or equal to 140/90 on a stable dose of
             ACE inhibitor or ARB for at least 1 month or greater than or equal to 75 percent of
             measurements before the entry of the study. The rationale is that uncontrolled
             hypertension can exacerbate proteinuria.

        EXCLUSION CRITERIA:

          -  Pregnancy, breastfeeding, or unwillingness to use at least two contraceptive methods
             (at least one of which must be primary, including tubal ligation, partner vasectomy,
             oral contraceptives, implanted contraceptives, and intrauterine device). The rationale
             is that retinoids are teratogenic and are excreted in breast milk.

          -  Abnormal liver function test, including aspartate aminotransferase (AST), alanine
             aminotransferase (ALT), total bilirubin, or protime. The rationale is that retinoids
             can be hepatotoxic. The only exception will be the following: if the cause of
             abnormality of liver function tests (LFT) is felt to be due to a specific hepatotoxic
             drug such as a statin and the levels are less than 2 times the upper limit of the
             normal AND normalize upon holding the offending drug, patients may be considered for
             study participation after consultation with hepatology service.

          -  Hypertriglyceridemia greater than 500 mg/dL despite statin/fibrate therapy. The
             rationale is that retinoids can increase lipids, particularly triglyceride as this can
             lead to pancreatitis.

          -  Any medical conditions requiring concurrent immunosuppression, as this pilot study is
             designed to evaluate the effect of retinoids as a monotherapy.

          -  Any medical conditions requiring concurrent use of tetracycline, minocycline, or
             doxycycline, due to enhanced risk of increased intracranial pressure.

          -  Hypersensitivity to retinoids.

          -  Presence of any unstable cardiovascular disease, uncontrolled diabetes with hemoglobin
             A1c greater than 8 percent, chronic inflammatory or infectious conditions except HIV-1
             infection. Retinoids have been associated with chest pain of unclear etiology,
             increased serum glucose, myelosuppression and increased risk of infection. The
             etiology of infection is not clear but may be related to myelosuppression.

          -  Those with HIV-1 infection must not have any evidence for opportunistic infectious
             complications and have cluster of differentiation 4 (CD4) count greater than or equal
             to 200. Both tretinoin and isotretinoin have been safely studied in HIV-infected
             patients for other indications.

          -  glomerular filtration rate (GFR) less than 40 ml/min/1.73m(2) estimated by 5-variable
             Modification of Diet in Renal Disease (MDRD) equation, as the metabolites of retinoids
             are excreted in part in urine, and there is a concern for increased toxicity. In
             participants less than 18 years of age, we will use Schwartz equation.

          -  Expansion of glomerulus or interstitial formation on the biopsy.

          -  Untreated depression, as retinoids have been associated with depression, suicidal
             ideation, and aggressive behavior. If patients manifest significant depressive
             symptoms, they will be included in the study only if assessed and agreed by a
             psychiatrist (either at NIH or other) and if they have regular follow-up visits with a
             psychiatrist.

          -  Factors that increase the risk of renal biopsy. These include the following:
             unwillingness to accept blood transfusion, bleeding diathesis, single kidney, small
             kidneys (less than 9.5 cm).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey B Kopp, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2005-DK-0015.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>WILSON JG, ROTH CB, WARKANY J. An analysis of the syndrome of malformations induced by maternal vitamin A deficiency. Effects of restoration of vitamin A at various times during gestation. Am J Anat. 1953 Mar;92(2):189-217.</citation>
    <PMID>13030424</PMID>
  </reference>
  <reference>
    <citation>Lelièvre-Pégorier M, Vilar J, Ferrier ML, Moreau E, Freund N, Gilbert T, Merlet-Bénichou C. Mild vitamin A deficiency leads to inborn nephron deficit in the rat. Kidney Int. 1998 Nov;54(5):1455-62.</citation>
    <PMID>9844121</PMID>
  </reference>
  <reference>
    <citation>Kriz W, Elger M, Nagata M, Kretzler M, Uiker S, Koeppen-Hageman I, Tenschert S, Lemley KV. The role of podocytes in the development of glomerular sclerosis. Kidney Int Suppl. 1994 Feb;45:S64-72. Review.</citation>
    <PMID>8158902</PMID>
  </reference>
  <verification_date>October 4, 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2004</study_first_submitted>
  <study_first_submitted_qc>December 1, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2004</study_first_posted>
  <results_first_submitted>June 8, 2017</results_first_submitted>
  <results_first_submitted_qc>December 12, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">December 13, 2017</results_first_posted>
  <last_update_submitted>December 12, 2017</last_update_submitted>
  <last_update_submitted_qc>December 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glomerulosclerosis</keyword>
  <keyword>Proteinuria</keyword>
  <keyword>Fibrosis</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Nephrotic Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glomerulosclerosis, Focal Segmental</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isotretinoin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The stored samples for this trial include plasma, urine, and renal biopsy samples. The plasma and urine are collected for cytokine measurement. Renal biopsy is done to evaluate histologic and ultrastructural changes. Samples/Data will be shared with collaborating investigators.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Isotretinoin</title>
          <description>Subjects will be treated with isotretinoin initially at 1mg/kg for the first 4 weeks and then dose will escalate to a higher dose only if subjects have tolerated the lower dose.
In younger patients of 16 and 17 years of age, the dose will be started at 1 mg/kg and will remain at this dose without escalation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Started Isotretinoin</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>elevated liver enzymes</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Low urine PCR</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Low epidermal growth factor receptor</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Isotretinoin</title>
          <description>subjects will be treated with iIsotretinoin.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Protein, Urine</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="626.42" spread="642.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Creatinine, Urine</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.37" spread="43.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Protein/Creatinine Ratio, Urine</title>
          <units>g/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.42" spread="4.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Proteinuria at Week 24 From Baseline</title>
        <description>Change of proteinuria at Week 24 compared to the baseline using protein/creatinine ratio (PCR)</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>A total of 7 patients is analyzed due to 1 withdrawal.</population>
        <group_list>
          <group group_id="O1">
            <title>Isotretinoin</title>
            <description>oral isotretinoin</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Proteinuria at Week 24 From Baseline</title>
          <description>Change of proteinuria at Week 24 compared to the baseline using protein/creatinine ratio (PCR)</description>
          <population>A total of 7 patients is analyzed due to 1 withdrawal.</population>
          <units>g/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.42" spread="4.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.67" spread="5.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Are in Complete Remission (CR) or Partial Remission (PR) at 6 Months or at the End of One Year.</title>
        <description>Based on 24hour proteinuria, response outcomes are defined as CR (complete remission): &lt;0.3 g/g PR (partial remission): 50% fall from baseline and &lt;2.0 g/g</description>
        <time_frame>End of one year from baseline</time_frame>
        <population>Seven out of 8 subjects who were treated with isotretinoin completed Week 24. One out of the 7 subjected who completed Week 24 did not complete the whole study.</population>
        <group_list>
          <group group_id="O1">
            <title>Isotretinoin</title>
            <description>oral isotretinoin</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Are in Complete Remission (CR) or Partial Remission (PR) at 6 Months or at the End of One Year.</title>
          <description>Based on 24hour proteinuria, response outcomes are defined as CR (complete remission): &lt;0.3 g/g PR (partial remission): 50% fall from baseline and &lt;2.0 g/g</description>
          <population>Seven out of 8 subjects who were treated with isotretinoin completed Week 24. One out of the 7 subjected who completed Week 24 did not complete the whole study.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>18 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Isotretinoin</title>
          <description>Subjects will be treated with isotretinoin .</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Edema Limbs</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Edema Trunk</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Periorbital edema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pacemaker placed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Vasovagal reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Night Blindness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hemorrhoidal hemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Conduction disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dexamethasone x4 doses: start MMF and CSA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hoarseness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Scalp pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Watering eyes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Cholesterol high</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia (knee/ankle)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Postnasal drip</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Creatinine Increased CTCAE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Dry skin (lips)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jeffery Kopp</name_or_title>
      <organization>National Institutes of Diabetes, Digestive, and Kidney Disorders</organization>
      <phone>301-594-3403</phone>
      <email>koppj@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

